At Synlogic, we are dedicated to bringing innovative living medicines to patients by using the tools and principles of synthetic biology to genetically re-program beneficial bacteria.Using our Synthetic Biotic platform, we are developing engineered probiotic bacteria to perform specific therapeutic functions with established links to disease. We can deliver these living, Synthetic Biotic medicines orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. We also aim to deliver Synthetic Biotic medicines at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors.
|Bank Name||Synlogic, Inc.|
|Chairman||Dr. Peter Barrett|
|CEO||Dr. Aoife M. Brennan MB, BCh, BAO, MMSc|